Effects of the Methylation Levels for the Breast Cancer Associated Genes BCSG1 and BRCA1 on Cellular Proliferation and Migration.

Objective: The aim of this study was to determine whether the methylation patterns of the breast cancer-specific gene 1 (BCSG1) and the breast cancer susceptibility gene 1 (BRCA1) can be used as biomarkers for predicting the occurrence and development of breast cancer. Methods: Methylation-specific polymerase chain reaction (PCR) was used to detect the methylation status of the BCSG1 and BRCA1 genes in ductal infiltrating carcinomas of the breast; carcinoma in situ of the breast; fibroadenoma of the breast and adjacent normal tissues. Quantitative real-time PCR and immunohistochemistry were used to detect the expression levels of BCSG1 and BRCA1. The BCSG1 and BRCA1 genes were knocked down by siRNA to study their effect of BCSG1 and BRCA1 on the behaviour of breast cancer cell lines. Results: The BCSG1 gene was hypomethylated in breast cancer tissues, and its mRNA as well as its protein levels showed elevated expression compared to normal adjacent tissues. In contrast, the BRCA1 gene was hypermethylated in breast cancer tissues and showed correspondingly decreased mRNA and protein expression levels. In vitro experiments demonstrated that BCSG1 could promote the proliferation and migration of breast cancer cells. After inhibiting the methylation, the expression of both the BCSG1 and BRCA1 genes were increased. Conclusion: Abnormal methylation patterns of the BCSG1 and BRCA1 genes are associated with the development of breast cancer. Thus, methylatedion analyses of these genes have biomarker potential for breast cancer prognoses.

Silencing of BCSG1 with specific siRNA via nanocarriers for breast cancer treatment.

Breast cancer is the most common cancer diagnosed in women worldwide. The current treatments for breast cancer, including surgery, radiotherapy and chemotherapy aim to destroy cancer cells, whereas they also cause damage to normal tissues and cells. Thus, an effective, safe and specific breast cancer treatment is urgently needed. The breast cancer-specific gene 1 (BCSG1) has been shown to be specific for the development of breast cancer and is a target for breast cancer diagnosis and treatment. It is expected to silence the expression of BCSG1 at the gene level for the purpose of treating breast cancer. The effect of RNAi technology on silencing target genes is comparable to gene knockout and has been widely used in animal experiments and plant genetic research. In the field of cancer therapy, numerous investigators have used siRNAs to specifically inhibit target genes, demonstrating that siRNAs can treat cancers at the molecular level. However, the delivery of siRNAs into humans needs to overcome multiple physiological barriers, limiting the clinical applications of siRNAs. This review focuses on the application of BCSG1 gene, siRNAs in cancer treatments, and the nanocarrier delivery system of siRNAs. The potential application and research value of BCSG1-specific siRNA in the treatment of breast cancer are discussed.

Expression and clinical pathological significance of BCSG1in invasive breast cancer / 中华内分泌外科杂志

Objective To investigate the expression of breast cancer specific gene 1( BCSG1) in breast cancer tissues and its clinical significance.Methods The expression of BCSG1in 51cases of breast cancer tissues and 35 cases of adjacent tissues was determined by fluorescence quantitative polymerase chain reaction (FQ-PCR) and immunohistochenistry.Results FQ-PCR showed the expression level of BCSG1mRNA in breast cancer and adjacent tissues was 1.072 ± 0.178 and 0.324± 0.135 respectively.Immunohistochemistry showed the expression rate of BCSG1protein in breast cancer and adjacent tissues was 74.5％ (38/51) and 14.3％ (5/35).The expression of BCSG1mRNA and protein was dramatically increased in breast cancer tissues compared with that in normal background breast tissues (P ＜ 0.05).BCSG1mRNA and protein expression was significantly different in patients with lymph node metastasis and higher Nottingham prognostic index (P ＜ 0.05 ),and there was no significant difference with the pathological type of breast cancer,or status of ER,PR,and c-erbB2 ( P ＞ 0.05 ).Conclusions BCSG1is highly expressed in breast cancer tissues,which is closely related to the development and clinical prognosis of breast cancer.BCSG1is very likely to play an important role in the pathogenesis of breast cancer.

A study on the expression of BCSG1, S100A4, VEGF in breast neoplasm / 中华普通外科杂志

Objective To study the expression of BCSG1 ,S100A4,VEGF in human breast cancer.Methods Immunohistochemistry technique SP method was used to examine breast fibroadenoma in 40 cases,breast invasive ductal carcinoma in 62 cases ( by armpit lymph node metastasis as 2 groups) and corresponding paratumor tissues in 48 cases. Results Among the 4 groups, there was significant difference ( P＜0.05 ) in the positive immunostaining rate of BCSG1 ,S100A4, VEGF. Conclusions In the breast invasive ductal carcinoma, the expression of BCSG1, S100A4 and VEGF increased. This suggested the invasive and metastasis ability of the neoplasm enhanced. The expression were in positive correlation with tumor pathology. Combined detection of BCSG1, S100A4, VEGF expression contributes to the early diagnosis and prognostic assessment of the carcinoma of the breast.

The value of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy for breast cancer / 中国普通外科杂志

Objective To study the value of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy(NC) for breast cancer.Methods The expression of BCSG1 in cancer tissue was assayed by immunohistochemistry and RT-PCR in 36 cases of breast cancer patients before and after receiving NC of CEF(cyclophosphamide,epirubicin and fluorouracil) regimen.The therapeutic response of NC was evaluated by morphological and pathological observation.The relationship between expression of BCSG1 and morphological response to NC was analyzed.Results Among the studied cases,the diameter of tumor significantly decreased(P